Recent news on Depocyt

DepoCyt Gains Full Approval  -  May 4, 2007
Cancer Consultants (press release),Full approval has been granted by the United States Food and Drug Administration (FDA) for Enzon Pharmaceuticals agent DepoCyt (cytarabine liposome

Enzon Reports First Quarter 2007 Results  -  May 2, 2007
American Digital Networks (press release),The FDA granted DepoCyt(R) a full approval for the treatment of patients with lymphomatous meningitis. DepoCyt was previously granted approval under the

Depocyt Granted Full Approval  -  Apr 24, 2007
Facts and Comparisons,The FDA has granted full approval to Enzon Pharmaceuticals’ Depocyt (cytarabine liposome) injection for the treatment of patients with lymphomatous

FDA Grants Full Approval for DepoCyt for the Treatment of ...  -  Apr 20, 2007
PharmaLive.com (press release),DepoCyt was originally approved under the Accelerated Approval regulations of Subpart H of the Food, Drug and Cosmetic Act, based on a preliminary

Enzon's DepoCyt gets full approval  -  Apr 20, 2007
United Press InternationalBRIDGEWATER, NJ, April 20 (UPI) -- Enzon said Friday the US Food and Drug Administration granted full approval to DepoCyt for treating lymphomatous

Enzon Receives DepoCyt Approval  -  Apr 20, 2007
Forbes,...company Enzon Pharmaceuticals Inc. said Friday the Food and Drug Administration granted full approval to its lymphomatus meningitis treatment DepoCyt.

Enzon Gets FDA Nod for Lymphoma Treatment  -  Apr 20, 2007
NJBIZ,Enzon Pharmaceuticals Inc. (Nasdaq: ENZN) today said that the Food and Drug Administration has granted full approval for its DepoCyt (cytarabine liposome

Biotech and pharma stocks rise; Enzon ahead  -  Apr 20, 2007
Therapeutics Daily (subscription) (press release),The company said early Friday that the Food and Drug Administration gave the green light for DepoCyt to treat lymphomatous meningitis,

ENZN: FDA Grants Full Approval for Cytarabine Liposome Injection  -  Apr 20, 2007
Therapeutics Daily (subscription) (press release),Enzon Pharmaceuticals, Inc. (ENZN) announced that the US Food and Drug Administration has granted full approval for DepoCyt (cytarabine liposome injection)

Market Report -- In Play (ENZN)  -  Apr 20, 2007
MSN MoneyEnzon says FDA grants full approval for DepoCyt for the treatment of lymphomatous meningitis Co announces that the FDA has granted full approval for DepoCyt

Enzon gets full FDA okay on meningitis drug  -  Apr 20, 2007
ReutersO: Quote, Profile, Research) said the US Food and Drug Administration has granted full approval for DepoCyt, its drug used for the treatment of a

Enzon Announces Timing of Annual Meeting of Shareholders  -  Apr 24, 2007
Business Wire (press release),Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several

News For Your Web Site  -  Apr 18, 2007
dBusinessNews Newark (press release),Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company’s drug development programs utilize several

Enzon’s PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 17, 2007
Business Wire (press release),Enzon has a portfolio of four marketed products, Oncaspar ® , DepoCyt ® , Abelcet ® and Adagen ® . The Company’s drug development programs utilize several

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
PipelineReview.com (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and DepoCyt(R) in the United States. In addition, Enzon also receives royalties

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
Business Wire (press release),Enzon's specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and DepoCyt® in the United States. In addition, Enzon also receives royalties on sales

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
PharmaLive.com (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt(R) in the United States. In addition, Enzon also receives royalties

Enzon Reports 2006 Financial Results and Accomplishments  -  Feb 13, 2007
Genetic Engineering News (press release),Sales of DepoCyt, a sustained-release formulation of the chemotherapeutic agent cytarabine arabinoside or ara-C used for the treatment of lymphomatous

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 4, 2007
dBusinessNews Newark (press release),Enzon’s specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Genetic Engineering News (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties

SkyePharma agrees to sell SD unit  -  Jan 10, 2007
San Diego Union Tribune,The San Diego unit's main products are DepoCyt, a cancer treatment, and DepoDur for post-operative pain. SkyePharma chief executive Frank Condella said the

SkyePharma injectables business sale may net $82 million  -  Jan 9, 2007
Pharma Times (subscription),The injectables business, which includes two marketed products, DepoCyt (cytarabine) for lymphomatous meningitis and the painkiller DepoDur (morphine),

SkyePharma aims for $82m with sale of injectable business  -  Jan 10, 2007
In-PharmaTechnologist.com,The injectables business is based in San Diego in the US and its products include DepoCyt (cytarabine)for lymphomatous meningitis and DepoDur (morphine

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
American Digital Networks (press release),Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In addition, Enzon also receives royalties

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
Business New Jersey (subscription),Enzon’s specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
Business Wire (press release),Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. In addition, Enzon also receives royalties

SkyePharma: Injectable Sale & Placing  -  Jan 9, 2007
PharmaLive.com (press release),Its products include DepoCyt®, a treatment for a lymphomatous meningitis, and DepoDurT for post operative pain. The ordinary shares in the Placing have not

Enzon Reports Third Quarter 2006 Results  Nov 2, 2006
Sales from the products segment, comprised of Oncaspar ® , Depocyt ® , Abelcet ® , and Adagen ® , increased slightly to $25.3 million for the three months ... -PharmaLive.com (press release), Light Revenue From Enzon  Nov 2, 2006
Sales in its products segment, which includes its drugs Oncaspar, Depocyt, Abelcet and Adagen, were up slightly to $25.3 million from $25.2 a year ago. ... -TheStreet.com Enzon Pharmaceuticals Announces Second Investigational New Drug ...  Nov 3, 2006
...adjacent diseases. Enzon's specialized sales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt (R) in the United States. In ... -PipelineReview.com (press release), Enzon Pharmaceuticals Announces Second Investigational New Drug ...  Nov 2, 2006
...diseases. Enzon’s specialized sales force markets Abelcet ® , Oncaspar ® , Adagen ® , and Depocyt ® in the United States. ... -Business Wire (press release), Enzon to Present at Bear Stearns 19th Annual Healthcare Conference ...  Sep 11, 2006
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ADAGEN(R), DEPOCYT(R), and ONCASPAR(R) in North America. In ... -dBusinessNews Newark

Enzon Pharmaceuticals Announces Effectiveness of Form S-3 ...  -  Nov 15, 2006
PharmaLive.com (press release),Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in the United States. In addition, Enzon also receives royalties

Enzon Pharmaceuticals Announces Effectiveness of Form S-3 ...  -  Nov 15, 2006
dBusinessNews Newark (press release),Enzon’s specialized sales force markets ABELCET®, ONCASPAR®, ADAGEN®, and DEPOCYT® in the United States. In addition, Enzon also receives royalties on sales

Enzon Reports Second Quarter 2006 Results; Company Continues to ...  Aug 1, 2006
Products segment sales, comprised of sales of Oncaspar(R),Depocyt(R) , Abelcet(R) , and Adagen(R) , increased to $24.5 millionfor the three months ended June 30 ... -Finanzen.net

Enzon Pharmaceuticals Announces Advancements in Its Oncology ...  Aug 1, 2006
...adjacent diseases. Enzon's specializedsales force markets Abelcet(R), Oncaspar(R), Adagen(R), and Depocyt(R)in the United States. In ... -Finanzen.net

NJ business briefs  Jul 28, 2006
Enzon is seeking to expand its line of cancer treatments, which includes Oncaspar for an aggressive form of leukemia and the chemotherapy drug Depocyt. ... -NorthJersey.com

ODAC Committee to Meet Nov. 8 On Accelerated Approval Commitments  Jun 30, 2006
Doxil® (liposomal doxorubicin), MedImmune’s Ethyol® (amifostine), Seragen’s Ontak® (denileukin diftitox), SkyePharma’s DepoCyt® (liposomal cytarabine ... -Cancer Consultants

Enzon Pharmaceuticals Announces Completion of Its Tender Offer for ...  Jul 7, 2006
...adjacent diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in the United States. In ... -dBusinessNews Newark

SkyePharma Reacquires European Rights for DepoBupivacaine(TM)  Jun 30, 2006
...days. For example in DepoCyt®/DepoCyte® the circulating half-life of the drug cytarabine is increased from 3.4 hours to 141 hours. ... -Yahoo! News



SkyePharma PLC - Preliminary Results Announcement for the Year ...  Apr 19, 2006
The injectables business includes DepoCyt(TM) and DepoDur(TM), both marketed products, and the lead injectable pipeline product DepoBupivacaine(TM). ... - PR Newswire

Enzon Reports Solid First Quarter; New Corporate Strategy Begins ...  May 2, 2006
Products segment sales, comprised of sales of ONCASPAR, DEPOCYT, ABELCET, and ADAGEN, increased to $24.3 million for the three months ended March 31, 2006 ... - Genetic Engineering News

SkyePharma PLC - Preliminary Results Announcement for the Year ...  Apr 19, 2006
The injectables business includes DepoCyt(TM) and DepoDur(TM), both marketed products, and the lead injectable pipeline product DepoBupivacaine(TM). - Black Enterprise

Losses pile up at struggling SkyePharma  Apr 19, 2006
It is also trying to sell its San Diego-based injectables business, which includes the marketed products DepoCyt for cancer complications, DepoDur for the ... - CityWire.co.uk

Enzon to Present at UBS Warburg Global Life Sciences Conference  Apr 20, 2006
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ADAGEN(R), DEPOCYT(R), and ONCASPAR(R) in North America. In ... - Genetic Engineering News

Enzon to Present at UBS Warburg Global Life Sciences Conference  Apr 20, 2006
...of therapeutics totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ADAGEN(R),DEPOCYT(R), and ... - Finanzen.net

SkyePharma's Loss Widens on Costs  Apr 19, 2006
The unit has two marketed products -- DepoCyt for a complication of cancer, and DepoDur for the treatment of post-surgical pain -- and other drugs in various ... - Wall Street Journal (subscription)





Enzon Initiates Clinical Program for ONCASPAR(R); FDA Completes ...  Apr 3, 2006
...totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R),ADAGEN(R), and DEPOCYT(R) in ... - Finanzen.net

Enzon Initiates Clinical Program for ONCASPAR(R); FDA Completes ...  Apr 3, 2006
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ... - Business Wire

‘Running The Business’ Now Again Focus For SkyePharma  Mar 14, 2006
There are two marketed products: DepoCyt, a cancer treatment, and Depodur, a controlled-release formulation of morphine for postoperative pain. ... - BioWorld Online (subscription)

SkyePharma defeats shareholder revolt  Mar 10, 2006
...pulmonary drug delivery businesses, and try to find a buyer for San Diego-based injectables unit, which has two marketed products - DepoCyt (cytarabine) for ... - Pharma Times (subscription)

Enzon to Present at Cowen 26th Annual Health Care Conference  Mar 3, 2006
...of therapeutics totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ADAGEN(R),DEPOCYT(R), and ... - Finanzen.net,

Enzon Reports Second Quarter Results and Transitions to Calendar ...  Feb 28, 2006
...segmentfor 2006. This segment is currently comprised of its four marketedproducts, ONCASPAR, DEPOCYT, ABELCET and ADAGEN. In 2006 ... - Finanzen.net,

SkyePharma Issues EGM Notice and Recommends Shareholders to Vote ...  Feb 17, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt(R) for a complication of cancer and Depodur(R) for the ... - PR Newswire,

SkyePharma defies rebels by appointing Karabelas to chair  Feb 2, 2006
The division, which makes DepoCyt to treat a complication of cancer and Depodur for post-surgery pain, has attracted interest from several bidders and is worth ... - Independent,

SkyePharma sinks as board defies rebels  Feb 2, 2006
...a three-month strategic review, the company said it is instead opting to sell its injectable drugs division, which comprises cancer drug DepoCyt and Depodur ... - Times Online

SkyePharma defies rebels by appointing Karabelas to chair  Feb 2, 2006
The division, which makes DepoCyt to treat a complication of cancer and Depodur for post-surgery pain, has attracted interest from several bidders and is worth ... - Independent

SkyePharma Announces Appointment of New Chairman and Outcome of ...  Feb 2, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt(R) for a complication of cancer and Depodur(R) for the ... - PR Newswire

Enzon Returns Rights to Transplantation Product to Fresenius ...  Jan 9, 2006
...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ... - dBusinessNews Newark

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional